Payment overview · 2025
General Payments
$572.03
30 reported records · 18 companies
Healthcare provider profile · identity verified
Thomas E Wojciechowski, MD
Allopathic & Osteopathic Physicians|Family Medicine · BOWLING GREEN, OH · NPI 1447248265
Verified facts
What the public records show
CMS Open Payments records show Thomas E Wojciechowski, MD received $572.03 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 851 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $99.97 | 17.5% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.72 | 12.2% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $57.04 | 10.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.55 | 9.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.58 | 6.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.18 | 5.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.79 | 5.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.07 | 4.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.35 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.96 | 4.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.13 | 3.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.15 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.45 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.51 | 2.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.20 | 2.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.18 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.72 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.48 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $529.53 | 29 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $85.79 | 5 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $57.04 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.55 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.89 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $47.92 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.58 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.58 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.07 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 106 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 120 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
58 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
851 | 72 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1268 | 197 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1133 | 151 |
| Eliquis | Apixaban | 851 | 72 |
| Furosemide | Furosemide | 837 | 167 |
| Potassium Chloride | Potassium Chloride | 822 | 108 |
| Sertraline Hcl | Sertraline Hcl | 772 | 91 |
| Gabapentin | Gabapentin | 761 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 742 | 118 |
| Lisinopril | Lisinopril | 584 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 548 | 79 |
| Januvia | Sitagliptin Phosphate | 544 | 36 |
| Omeprazole | Omeprazole | 528 | 77 |
| Donepezil Hcl | Donepezil Hcl | 467 | 62 |
| Trazodone Hcl | Trazodone Hcl | 435 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 431 | 78 |
| Warfarin Sodium | Warfarin Sodium | 417 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 380 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 344 | 67 |
| Quetiapine Fumarate | Quetiapine Fumarate | 342 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 339 | 48 |
| Metformin Hcl | Metformin Hcl | 325 | 52 |
| Buspirone Hcl | Buspirone Hcl | 312 | 59 |
| Memantine Hcl | Memantine Hcl | 284 | 38 |
| Famotidine | Famotidine | 278 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 270 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 266 | 45 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 254 | 44 |
| Lorazepam | Lorazepam | 253 | 52 |
| Tramadol Hcl | Tramadol Hcl | 249 | 34 |
| Carvedilol | Carvedilol | 233 | 45 |
| Losartan Potassium | Losartan Potassium | 225 | 41 |
| Mirtazapine | Mirtazapine | 221 | 40 |
| Baclofen | Baclofen | 215 | 23 |
| Simvastatin | Simvastatin | 212 | 30 |
| Allopurinol | Allopurinol | 208 | 42 |
| Cephalexin | Cephalexin | 206 | 95 |
| Prednisone | Prednisone | 206 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 191 | 39 |
| Glimepiride | Glimepiride | 191 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 187 | 22 |
| Risperidone | Risperidone | 187 | 13 |
| Divalproex Sodium | Divalproex Sodium | 186 | 24 |
| Xarelto | Rivaroxaban | 185 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 181 | 38 |
| Bumetanide | Bumetanide | 179 | 35 |
| Myrbetriq | Mirabegron | 179 | 20 |
| Meloxicam | Meloxicam | 176 | 24 |
| Novolog Flexpen | Insulin Aspart | 175 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 29 |
| Lamotrigine | Lamotrigine | 167 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 164 | 29 |
| Spironolactone | Spironolactone | 163 | 33 |
| Alprazolam | Alprazolam | 155 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 146 | 19 |
| Amoxicillin | Amoxicillin | 144 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 143 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 29 |
| Aripiprazole | Aripiprazole | 125 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 122 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 121 | 16 |
| Jardiance | Empagliflozin | 120 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 114 | 18 |
| Fenofibrate | Fenofibrate | 113 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 109 | 55 |
| Levetiracetam | Levetiracetam | 109 | 18 |
| Latanoprost | Latanoprost | 107 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 19 |
| Farxiga | Dapagliflozin Propanediol | 106 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 105 | 61 |
| Montelukast Sodium | Montelukast Sodium | 105 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 105 | 44 |
| Ezetimibe | Ezetimibe | 104 | 15 |
| Olanzapine | Olanzapine | 98 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 17 |
| Topiramate | Topiramate | 95 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 19 |
| Albuterol Sulfate | Albuterol Sulfate | 90 | 56 |
| Pregabalin | Pregabalin | 90 | suppressed |
| Primidone | Primidone | 90 | 13 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 89 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 42 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 84 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 83 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 83 | 49 |
| Loperamide | Loperamide Hcl | 82 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 81 | 42 |
| Nystatin | Nystatin | 81 | 25 |
| Alendronate Sodium | Alendronate Sodium | 79 | 11 |
| Clonazepam | Clonazepam | 79 | 12 |
| Ibuprofen | Ibuprofen | 77 | 32 |
| Finasteride | Finasteride | 76 | 15 |
| Lacosamide | Lacosamide | 76 | suppressed |
| Levofloxacin | Levofloxacin | 76 | 51 |
| Azithromycin | Azithromycin | 75 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 74 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 73 | 14 |
| Hydrocortisone | Hydrocortisone | 72 | 35 |
| Midodrine Hcl | Midodrine Hcl | 72 | 18 |
| Metformin Hcl Er | Metformin Hcl | 71 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | suppressed |
| Bupropion Xl | Bupropion Hcl | 67 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 67 | 21 |
| Atenolol | Atenolol | 66 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 13 |
| Linzess | Linaclotide | 65 | suppressed |
| Fluconazole | Fluconazole | 64 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 35 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 63 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 61 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 61 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 58 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 25 |
| Sodium Chloride | 0.9 % Sodium Chloride | 54 | 15 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 13 |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Cyclosporine | Cyclosporine | 46 | suppressed |
| Lidocaine | Lidocaine | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | suppressed |
| Acyclovir | Acyclovir | 42 | suppressed |
| Calcitriol | Calcitriol | 42 | suppressed |
| Metolazone | Metolazone | 42 | 17 |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Sucralfate | Sucralfate | 40 | suppressed |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 38 | suppressed |
| Vraylar | Cariprazine Hcl | 38 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 37 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 36 | suppressed |
| Nyamyc | Nystatin | 36 | 19 |
| Rivastigmine | Rivastigmine Tartrate | 36 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 36 | 13 |
| Acetic Acid | Acetic Acid | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Diazepam | Diazepam | 33 | 12 |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 32 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 30 | 20 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 28 | 21 |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Acetylcysteine | Acetylcysteine | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Paliperidone Er | Paliperidone | 27 | suppressed |
| Tacrolimus | Tacrolimus | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Fycompa | Perampanel | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 25 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Silodosin | Silodosin | 25 | suppressed |
| Clobazam | Clobazam | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Klayesta | Nystatin | 23 | 13 |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Zonisamide | Zonisamide | 23 | suppressed |
| Enulose | Lactulose | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 21 | suppressed |
| Cimetidine | Cimetidine | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 21 | suppressed |
| Water | Water For Irrigation,sterile | 21 | suppressed |
| Cholestyramine Light | Cholestyramine | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 19 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 13 |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 14 |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 18 |
| Anastrozole | Anastrozole | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Levemir | Insulin Detemir | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 16 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Acetazolamide Er | Acetazolamide | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | suppressed |
| Thiothixene | Thiothixene | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Norgestimate-Ethinyl Estradiol | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Prevalite | Cholestyramine | 13 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 12 | 12 |
| Misoprostol | Misoprostol | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Vienva | Levonorgestrel/Ethin.Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $572.03 · 30 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, AREXVY, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZAVZPRET, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error